Piper Sandler Keeps Their Buy Rating on Solventum Corporation (SOLV)

Piper Sandler analyst Jason Bednar maintained a Buy rating on Solventum Corporation today and set a price target of $98.00.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Bednar is an analyst with an average return of -6.0% and a 35.64% success rate. Bednar covers the Healthcare sector, focusing on stocks such as NovoCure, Merit Medical Systems, and Align Tech.

In addition to Piper Sandler, Solventum Corporation also received a Buy from TipRanks – PerPlexity’s PerPlexity Medical – Care Facilities in a report issued yesterday. However, on the same day, TipRanks – xAI reiterated a Hold rating on Solventum Corporation (NYSE: SOLV).

Based on Solventum Corporation’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2 billion and a net profit of $63 million. In comparison, last year the company earned a revenue of $2.08 billion and had a net profit of $31 million

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SOLV in relation to earlier this year. Earlier this month, Amy Mcbride Wendell, a Director at SOLV bought 1,475.00 shares for a total of $100,344.25.